Drugs / BW-1010
last change Sep 2021 re-read 2 minutes ago

BW-1010

Developed for
anthrax infection
Investigated by
BlueWillow Biologics · Porton Biopharma Ltd.

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04148118 Jan 2020 → Sep 2021 anthrax infection BlueWillow Biologics Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BW-1010 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04148118